A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

被引:27
|
作者
Hellerstein, Marc K. [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA 94110 USA
[3] KineMed Inc, Emeryville, CA 94608 USA
关键词
Drug discovery and development; Pathway-based discovery; Metabolic flux analysis; Exploiting complexity;
D O I
10.1016/j.ymben.2007.09.003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Contemporary drug discovery and development (DDD) is dominated by a molecular target-based paradigm. Molecular targets that are potentially important in disease are physically characterized; chemical entities that interact with these targets are identified by ex vivo high-throughput screening assays, and optimized lead compounds enter testing as drugs. Contrary to highly publicized claims, the ascendance of this approach has in fact resulted in the lowest rate of new drug approvals in a generation. The primary explanation for low rates of new drugs is attrition, or the failure of candidates identified by molecular target-based methods to advance successfully through the DDD process. In this essay, I advance the thesis that this failure was predictable, based on modern principles of metabolic control that have emerged and been applied most forcefully in the field of metabolic engineering. These principles, such as the robustness of flux distributions, address connectivity relationships in complex metabolic networks and make it unlikely a priori that modulating most molecular targets will have predictable, beneficial functional outcomes. These same principles also suggest, however, that unexpected therapeutic actions will be common for agents that have any effect (i.e., that complexity can be exploited therapeutically). A potential operational solution (pathway-based DDD), based on observability rather than predictability, is described, focusing on emergent properties of key metabolic pathways in vivo. Recent examples of pathway-based DDD are described. In summary, the molecular target-based DDD paradigm is built on a naive and misleading model of biologic control and is not heuristically adequate for advancing the mission of modern therapeutics. New approaches that take account of and are built on principles described by metabolic engineers are needed for the next generation of DDD. (C) 2007 Published by Elsevier Inc.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [21] An in Silico Approach for Integrating Phenotypic and Target-Based Approaches in Drug Discovery
    Iwata, Hiroaki
    Kojima, Ryosuke
    Okuno, Yasushi
    MOLECULAR INFORMATICS, 2020, 39 (1-2)
  • [22] Triazole-fused pyrimidines in target-based anticancer drug discovery
    Dai, Xing-Jie
    Xue, Lei-Peng
    Ji, Shi-Kun
    Zhou, Ying
    Gao, Ya
    Zheng, Yi-Chao
    Liu, Hui-Min
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 249
  • [23] Drug Discovery in the Age of Artificial Intelligence: Transformative Target-Based Approaches
    Patne, Akshata Yashwant
    Dhulipala, Sai Madhav
    Lawless, William
    Prakash, Satya
    Mohapatra, Shyam S.
    Mohapatra, Subhra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [24] Reductionism and proxy failure: From neuroscience to target-based drug discovery
    Sadri, Arash
    Paknezhad, Sepideh
    BEHAVIORAL AND BRAIN SCIENCES, 2024, 47
  • [25] Surface plasmon resonance as a fascinating approach in target-based drug discovery and development
    Das, Shibam
    Singh, Sukhwinder
    Chawla, Viney
    Chawla, Pooja A.
    Bhatia, Rohit
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2024, 171
  • [26] Target-based discovery of a broad-spectrum flukicide
    Sprague, Daniel J.
    Park, Sang-Kyu
    Gramberg, Svenja
    Bauer, Lisa
    Rohr, Claudia M.
    Chulkov, Evgeny G.
    Smith, Emery
    Scampavia, Louis
    Spicer, Timothy P.
    Haeberlein, Simone
    Marchant, Jonathan S.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2024, 31 (09) : 1386 - 1393
  • [27] TARGET-BASED DRUG DISCOVERY IN MALARIA: A NEW WAY TO IMPLEMENT AN OLD STRATEGY
    Alvaro, Elena Fernandez
    Harupa, Anke
    Kaushansky, Alexis
    Penzo, Maria
    Penzo, Maria
    Baker, David
    Herreros, Esperanza
    Ballell-Pages, Lluis
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 90 - 90
  • [28] Target-based approaches for the discovery of new antimycobactrial drugs
    Borsari, Chiara
    Ferrari, Stefania
    Venturelli, Alberto
    Costi, Maria Paola
    DRUG DISCOVERY TODAY, 2017, 22 (03) : 576 - 584
  • [29] Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies
    Moshawih, Said
    Lim, Ai Fern
    Ardianto, Chrismawan
    Goh, Khang Wen
    Kifli, Nurolaini
    Goh, Hui Poh
    Jarrar, Qais
    Ming, Long Chiau
    BIOMOLECULES, 2022, 12 (07)
  • [30] Pathway-based discovery of genetic interactions in breast cancer
    Wang, Wen
    Xu, Zack Z.
    Costanzo, Michael
    Boone, Charles
    Lange, Carol A.
    Myers, Chad L.
    PLOS GENETICS, 2017, 13 (09):